Abstract: The present invention relates to a test support method which is a means for predicting whether or not pathological complete response (pCR) will be attained when a preoperative chemotherapy with an anticancer drug is performed, the method using a sample (breast cancer tissue section) collected from a breast cancer patient to be subjected to the preoperative chemotherapy. The test support method includes: [1] the step of acquiring a fluorescence image of a breast cancer tissue section, which fluorescence image shows bright spots of fluorescent nanoparticles labeling one or more kinds of breast cancer-related proteins; [2] the step of acquiring at least one index relating to the expression level(s) of the breast cancer-related protein(s) on the basis of the bright spots of the fluorescence image; and [3] the step of acquiring information for predicting pCR by performing an analysis using the above-described at least one index.

Abstract: A separation device is a separation device that separates dielectric particles. The separation device includes a flow channel (20), a plurality of three-dimensionally shaped electrodes (31, 32), a power supply (40), and a controller. The flow channel (20) feeds a suspension containing the dielectric particles. The plurality of three-dimensionally shaped electrodes (31, 32) is arranged in the flow channel (20) and extends in a height direction of the flow channel (20). The power supply (40) applies an AC voltage with a predetermined frequency to the plurality of electrodes (31, 32) so as to generate dielectrophoresis of the dielectric particles. The controller controls the power supply.

Abstract: An analysis device (200) analyzes a crossover frequency at which a dielectrophoretic force on dielectric particles switches from a repulsive force to an attractive force or from the attractive force to the repulsive force, comprising a flow channel (5), a pair of electrodes (22, 23), a power supply (24), an imaging unit (25) and an analyzer (26). Through the flow channel (5), a sample solution containing the dielectric particles in the dielectrophoretic liquid flows. The pair of electrodes (22, 23) are arranged in the first channel. The power supply (24) applies a frequency-modulated AC voltage to the first electrodes (22, 23). The imaging unit (25) captures an image of a movement trajectory of each of the dielectric particles flowing between the electrodes (22, 23) in the flow channel. The analyzer (26) obtains the crossover frequency of the dielectric particles based on the captured image of the movement trajectory.

Abstract: The present invention provides a subject information accumulating apparatus that conducts diagnosis with high reliability. The subject information accumulating apparatus includes compression plates configured to compress a subject, an irradiation unit configured to apply light, an acoustic wave detector configured to receive acoustic waves generated within a subject and to output an electric signal, and a controller configured to perform control so that an acoustic wave image and pressure information are displayed on a display unit.

Abstract: An analysis device (200) analyzes a crossover frequency at which a dielectrophoretic force on dielectric particles switches from a repulsive force to an attractive force or from the attractive force to the repulsive force, comprising a flow channel (5), a pair of electrodes (22, 23), a power supply (24), an imaging unit (25) and an analyzer (26). Through the flow channel (5), a sample solution containing the dielectric particles in the dielectrophoretic liquid flows. The pair of electrodes (22, 23) are arranged in the first channel. The power supply (24) applies a frequency-modulated AC voltage to the first electrodes (22, 23). The imaging unit (25) captures an image of a movement trajectory of each of the dielectric particles flowing between the electrodes (22, 23) in the flow channel. The analyzer (26) obtains the crossover frequency of the dielectric particles based on the captured image of the movement trajectory.

Abstract: Provided is a cancer development risk assessment device (1) capable of determining the possibility of cancer development in a subject to be assessed in short time. The cancer development risk assessment device (1) includes a measurement unit (3) and a controller (4). The measurement unit (3) is configured to measure concentrations of a plurality of types of target components included in exhaled air collected from a subject to be assessed. The controller (4) is configured to calculate an assessment score correlated to the possibility of cancer being developed in the subject to be assessed based on measurement results of the concentrations obtained by the measurement unit (3).

Abstract: The present invention relates to a test support method which is a means for predicting whether or not pathological complete response (pCR) will be attained when a preoperative chemotherapy with an anticancer drug is performed, the method using a sample (breast cancer tissue section) collected from a breast cancer patient to be subjected to the preoperative chemotherapy. The test support method includes: [1] the step of acquiring a fluorescence image of a breast cancer tissue section, which fluorescence image shows bright spots of fluorescent nanoparticles labeling one or more kinds of breast cancer-related proteins; [2] the step of acquiring at least one index relating to the expression level(s) of the breast cancer-related protein(s) on the basis of the bright spots of the fluorescence image; and [3] the step of acquiring information for predicting pCR by performing an analysis using the above-described at least one index.

Abstract: This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator.

Abstract: A subject information acquisition device includes a first holding member that holds a subject of a patient, a first probe that detects an acoustic wave having propagated through the first holding member and that performs a scanning operation, a first holding-member support located on a patient side from a scanning range of the first probe and that reduces bending of the first holding member, and a second probe located on the patient side from the scanning range of the first probe.

Abstract: The present invention provides a subject information accumulating apparatus that conducts diagnosis with high reliability. The subject information accumulating apparatus includes compression plates configured to compress a subject, an irradiation unit configured to apply light, an acoustic wave detector configured to receive acoustic waves generated within a subject and to output an electric signal, and a controller configured to perform control so that an acoustic wave image and pressure information are displayed on a display unit.

Abstract: An administration method comprising: determining a cancer type through (i) first data indicating that an Estrogen Receptor (ER) is negative and a Human Epidermal growth factor Receptor-2 (Her2) is negative, or (ii) second data indicating that at least one of the ER and the Her2 is positive; and when the cancer type is determined through (i) the first data indicating that the ER is negative and the Her2 is negative: first performing a docetaxel administration cycle comprising administrating docetaxel to a patient multiple times at certain intervals; and then performing a 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) administration cycle comprising administrating 5-fluorouracil, epirubicin, and cyclophosphamide to the patient multiple times at certain intervals, and when the cancer type is determined through (ii) the second data indicating that at least one of the ER and Her2 is positive: first performing the FEC administration cycle; and then performing the docetaxel administration cycle.

Abstract: Provided is an agent or a food or drink for reducing the risk of developing breast cancer. An agent for reducing the risk of developing breast cancer which comprises a composition containing living cells of Lactobacillus casei.

Abstract: This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator.

Abstract: A subject information acquisition device includes a first holding member that holds a subject of a patient, a first probe that detects an acoustic wave having propagated through the first holding member and that performs a scanning operation, a first holding-member support located on a patient side from a scanning range of the first probe and that reduces bending of the first holding member, and a second probe located on the patient side from the scanning range of the first probe.

Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.

Abstract: Provided is an agent or a food or drink for reducing the risk of developing breast cancer. An agent for reducing the risk of developing breast cancer which comprises a composition containing living cells of Lactobacillus casei.

Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.

Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.

Abstract: There was no device that proposes a method for administrating anti-cancer drugs according to each of cancer types. An administration method proposing device (100) includes an input unit (101) that receives an input of the cancer type of a cancer patient, an administration procedure determination unit (102) that determines the administration order of an FEC (F: 5-fluorouracil, E: epirubicin, and C: cyclophosphamide) administration cycle and a docetaxel administration cycle, and a display unit (103) that displays the administration order of the FEC administration cycle and the docetaxel administration cycle, as a result of the determination by the administration procedure determination unit (102).

Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.